Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABNASDAQ:ITCINYSE:RDYNASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$19.08-1.2%$19.90$17.24▼$30.41$12.23B1.041.10 million shs1.71 million shsITCIIntra-Cellular Therapies$131.87$131.76$64.09▼$131.98$14.05B0.691.49 million shsN/ARDYDr. Reddy's Laboratories$14.16+0.4%$13.33$12.26▼$16.89$11.82B0.331.49 million shs1.43 million shsSRPTSarepta Therapeutics$35.74-1.3%$64.03$34.90▼$173.25$3.51B0.851.68 million shs5.21 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S-3.11%-5.44%+2.66%-1.93%-33.78%ITCIIntra-Cellular Therapies0.00%0.00%0.00%+3.05%+98.84%RDYDr. Reddy's Laboratories+1.11%+4.18%+6.55%+1.88%+0.70%SRPTSarepta Therapeutics-0.47%-22.57%-29.06%-67.03%-72.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S4.1538 of 5 stars4.33.00.00.03.30.03.1ITCIIntra-Cellular Therapies0.6939 of 5 stars1.10.00.04.50.61.70.6RDYDr. Reddy's Laboratories2.0282 of 5 stars2.32.01.70.03.00.01.9SRPTSarepta Therapeutics4.7013 of 5 stars4.42.00.04.21.82.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.69Moderate Buy$39.17105.28% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideRDYDr. Reddy's Laboratories 2.50Moderate Buy$17.0020.06% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$126.74254.61% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, ITCI, GMAB, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025SRPTSarepta TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy$188.00 ➝ $85.005/8/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$115.00 ➝ $100.005/8/2025SRPTSarepta TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline$50.005/7/2025SRPTSarepta TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$87.00 ➝ $58.005/7/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$178.00 ➝ $100.005/7/2025SRPTSarepta TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$112.00 ➝ $98.005/7/2025SRPTSarepta TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$163.00 ➝ $81.005/7/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$184.00 ➝ $123.005/7/2025SRPTSarepta TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $70.005/7/2025SRPTSarepta TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$182.00 ➝ $113.004/9/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $37.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$21.64B0.57$1.29 per share14.80$8.04 per share2.37ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RDYDr. Reddy's Laboratories$311.31B0.04$1.07 per share13.25$4.50 per share3.15SRPTSarepta Therapeutics$2.23B1.57N/AN/A$9.19 per share3.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7610.9710.722.6536.30%16.78%13.79%N/AITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ARDYDr. Reddy's Laboratories$668M$0.6622.5517.27N/A17.25%17.87%12.32%7/25/2025 (Estimated)SRPTSarepta Therapeutics-$535.98M-$2.6928.593.27N/A7.43%11.00%3.35%N/ALatest SRPT, ITCI, GMAB, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.080.56%N/A12.12%N/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.255.24ITCIIntra-Cellular TherapiesN/A7.667.51RDYDr. Reddy's Laboratories0.021.921.38SRPTSarepta Therapeutics0.933.843.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%ITCIIntra-Cellular Therapies92.33%RDYDr. Reddy's Laboratories3.85%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%RDYDr. Reddy's Laboratories2.00%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S1,660641.20 million651.58 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRDYDr. Reddy's Laboratories24,800834.77 million818.05 millionOptionableSRPTSarepta Therapeutics84098.28 million88.17 millionOptionableSRPT, ITCI, GMAB, and RDY HeadlinesRecent News About These CompaniesBearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimatesMay 14 at 9:11 AM | finance.yahoo.comPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore (SRPT)May 14 at 8:30 AM | marketbeat.comEnsign Peak Advisors Inc Has $21.10 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 14 at 5:26 AM | marketbeat.comSarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular DystrophyMay 13 at 6:07 PM | finance.yahoo.comJ. Goldman & Co LP Purchases 8,628 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 13 at 8:22 AM | marketbeat.comJanus Henderson Group PLC Sells 30,188 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 13 at 8:05 AM | marketbeat.com2 Stocks Near Their 52-Week Lows That Still Aren't Worth BuyingMay 13 at 4:14 AM | fool.comSarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside PotentialMay 12 at 10:30 PM | finance.yahoo.comSarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside PotentialMay 11 at 5:20 PM | insidermonkey.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Lifted by Farallon Capital Management LLCMay 11 at 7:39 AM | marketbeat.comBokf Na Acquires 11,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 11 at 6:01 AM | marketbeat.comStifel Financial Corp Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 11 at 4:12 AM | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Sells Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 11 at 2:07 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Evercore ISIMay 10, 2025 | marketbeat.comFred Alger Management LLC Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 10, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTMay 10, 2025 | accessnewswire.comWhy Sarepta Therapeutics, Inc.’s (SRPT) Stock Is Up 6.43%May 10, 2025 | aaii.comBalyasny Asset Management L.P. Sells 218,359 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 10, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 10, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $125.00 by Analysts at Needham & Company LLCMay 10, 2025 | americanbankingnews.comSarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)May 10, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRPT, ITCI, GMAB, and RDY Company DescriptionsGenmab A/S NASDAQ:GMAB$19.08 -0.23 (-1.19%) As of 04:00 PM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Dr. Reddy's Laboratories NYSE:RDY$14.16 +0.06 (+0.43%) As of 03:48 PM EasternDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Sarepta Therapeutics NASDAQ:SRPT$35.74 -0.46 (-1.27%) As of 04:00 PM EasternSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
